FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series C / Biotech startups that raised Series C in the United States

Biotech startups that raised Series C in the United States

Updated 16 Nov 2026

Reset
Biotech startups that raised Series C in the United States
One-time CSV
  • 339 funded companies, 318 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-c~united-states.csv339 rows × 18 columns
CompanyCityLast roundAmountDate
Delix TherapeuticsBostonSeries C$100.0M2026-11-09
BigHat BiosciencesSan MateoSeries C$75.0M2026-09-24
ImmunoPhotonicsSt LouisSeries C$10.1M2026-09-01
Bridge to LifeNorthbrookSeries C$110.0M2026-08-12
Ratio TherapeuticsBostonSeries C$70.0M2026-07-31
Chai DiscoverySan FranciscoSeries C$400.0M2026-07-14
CellanomeRedwood CitySeries C$75.9M2026-06-18
Triveni BioWatertownSeries C$65.0M2026-06-17

8 rows of the CSV in 5 of its 18 columns.

339
Startups
$38.6B
Total raised
29
Funded in the last 12 months
$2.3B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 339
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
BigHat Biosciences BigHat Biosciences develops antibody and protein therapeutics using machine learning and automated experimentation. Artificial intelligence San Mateo Series C $75.0M 2026-09-24 $174.3M Andreessen Horowitz, Gaingels, 8VC +2 51 to 100 2019
ImmunoPhotonics ImmunoPhotonics is a biotechnology company that develops cancer immunotherapies to stimulate immune responses against tumors. Biotech St Louis Series C $10.1M 2026-09-01 $42.0M TCA Venture Group, Cultivation Capital, Arch Grants +1 11 to 50 2012
Bridge to Life Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. Biotech Northbrook Series C $110.0M 2026-08-12 $167.5M Perceptive Advisors 101 to 250 2005
Ratio Therapeutics Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. Biotech Boston Series C $70.0M 2026-07-31 $160.0M Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments 11 to 50 2021
Chai Discovery Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. Artificial intelligence San Francisco Series C $400.0M 2026-07-14 $631.0M Thrive Capital, OpenAI 11 to 50 2024
Cellanome Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. Biotech Redwood City Series C $75.9M 2026-06-18 $289.6M Premji Invest, Synetro Group 51 to 100 2020
Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
Cerevance Cerevance develops novel therapeutics for neurological diseases. Biotech Boston Series C $20.0M 2026-05-12 $209.5M Google Ventures, Casdin Capital, Foresite Capital +1 51 to 100 2016
Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
Terrestrial Bio Terrestrial Bio develops biomedical innovations aimed at improving access to vaccines. Biotech Cambridge Series C $50.0M 2026-03-26 $180.9M RA Capital Management, National Institutes of Health, The Engine 11 to 50 2012
Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
Loyal Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. Biotech San Francisco Series C $100.0M 2026-02-11 $237.1M Khosla Ventures, First Round Capital, Quiet Capital +1 101 to 250 2019
Colossal Biosciences Unicorn Colossal Biosciences uses gene editing technology to pursue de-extinction of species. Biotech Austin Series C $60.0M 2026-02-03 $628.1M Boost VC, Capital Factory, Climate Capital 101 to 250 2021
Beacon Therapeutics Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. Biotech Alachua Series C $75.0M 2026-01-08 $365.1M Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 101 to 250 2023
Culture Biosciences Culture Biosciences provides automated systems for bioprocess development of biological products. Biotech San Francisco Series C $80.0M 2025-12-16 $101.6M Y Combinator, National Science Foundation, BoxGroup +1 101 to 250 2016
Aspen Neuroscience Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. Biotech San Diego Series C $115.0M 2025-11-20 $387.0M Google Ventures, OrbiMed, EDBI +2 101 to 250 2018
Lumen Bioscience Lumen Bioscience discovers, develops, and manufactures biologic drugs and vaccine candidates. Biotech Seattle Series C $30.0M 2025-10-08 $97.0M US Department of Energy, WestRiver Group 101 to 250 2017
TORL BioTherapeutics TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. Biotech Culver City Series C $96.0M 2025-10-07 $412.0M Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 51 to 100 2018
Kromatid Kromatid develops molecular cytogenetics assays and reagents to study genetic abnormalities and diseases. Biotech Longmont Series C $8.0M 2025-08-20 $28.1M BroadOak Capital Partners, First Capital Ventures 11 to 50 2007
Gameto Gameto develops cell-engineered therapeutics for the female reproductive system. Biotech New York Series C $44.0M 2025-08-12 $117.0M FJ Labs, Insight Partners, Gaingels +2 11 to 50 2020
Attovia Therapeutics Attovia Therapeutics develops biotherapeutics for immune-mediated diseases. Biotech San Carlos Series C $90.0M 2025-04-15 $255.0M Goldman Sachs Asset Management, Cormorant Asset Management, Marshall Wace +2 11 to 50 2023
Biolinq Biolinq develops a wearable biosensor platform that measures blood level information. Biotech San Diego Series C $100.0M 2025-03-19 $276.3M Alpha Wave Global, Pegasus Tech Ventures, M Ventures 51 to 100 2012
Umoja Biopharma Umoja Biopharma develops immunotherapies intended to treat cancer by engineering the body's own immune cells. Biotech Seattle Series C $100.0M 2025-01-14 $363.0M SoftBank Vision Fund, Temasek, Cormorant Asset Management +2 101 to 250 2019
ArsenalBio ArsenalBio develops programmable CAR T-cell therapies for solid tumors. Biotech South San Francisco Series C $325.0M 2024-09-04 $630.8M ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 251 to 500 2019
MBX Biosciences MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. Biotech Carmel Series C $63.5M 2024-08-05 $238.4M New Enterprise Associates, RA Capital Management, OrbiMed +2 11 to 50 2019
Autobahn Therapeutics Autobahn Therapeutics develops restorative treatments for neuropsychiatric and neuroimmunologic disorders. Biotech San Diego Series C $100.0M 2024-07-24 $208.7M Insight Partners, Invus, Bristol-Myers Squibb +2 11 to 50 2017
Bluejay Therapeutics Bluejay Therapeutics is a private biopharmaceutical company developing cures for infectious diseases. Biotech San Mateo Series C $182.0M 2024-05-09 $242.2M RA Capital Management, Wellington Management, Novo Holdings +2 11 to 50 2019
Aardvark Therapeutics Aardvark Therapeutics develops small molecule drugs for obesity and rare genetic metabolic disorders. Biotech San Diego Series C $85.0M 2024-05-09 $129.0M Cormorant Asset Management, Vickers Venture Partners, Decheng Capital +1 11 to 50 2017

Table 1. Biotech startups that raised Series C in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 339.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 Chai Discovery Chai Discovery develops artificial intelligence models and software for protein engineering and molecular design. Artificial intelligence San Francisco Series C $400.0M 2026-07-14 $631.0M Thrive Capital, OpenAI 11 to 50 2024
2 Aspen Neuroscience Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. Biotech San Diego Series C $115.0M 2025-11-20 $387.0M Google Ventures, OrbiMed, EDBI +2 101 to 250 2018
3 Bridge to Life Bridge to Life develops organ preservation and perfusion solutions for transplant centers and procurement organizations. Biotech Northbrook Series C $110.0M 2026-08-12 $167.5M Perceptive Advisors 101 to 250 2005
4 Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
5 Cognito Therapeutics Cognito Therapeutics develops neurotechnology therapies that stimulate brain activity to treat neurodegenerative diseases. Biotech Cambridge Series C $105.0M 2026-03-05 $321.8M Morningside, FoundersX Ventures, IAG Capital Partners +1 11 to 50 2016
6 Delix Therapeutics Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. Biotech Boston Series C $100.0M 2026-11-09 $244.1M Gaingels, RA Capital Management, Dolby Family Ventures +2 11 to 50 2019
7 Loyal Loyal develops veterinary medicines to extend the healthy lifespan of senior dogs. Biotech San Francisco Series C $100.0M 2026-02-11 $237.1M Khosla Ventures, First Round Capital, Quiet Capital +1 101 to 250 2019
8 CereVasc CereVasc develops a minimally invasive treatment for communicating hydrocephalus. Biotech Charlestown Series C $85.0M 2026-06-04 $199.0M Perceptive Advisors, Bain Capital Life Sciences, ATON Partners 11 to 50 2014
9 Culture Biosciences Culture Biosciences provides automated systems for bioprocess development of biological products. Biotech San Francisco Series C $80.0M 2025-12-16 $101.6M Y Combinator, National Science Foundation, BoxGroup +1 101 to 250 2016
10 Cellanome Cellanome uses synthetic biology and informatics methods to analyze multi-omics data. Biotech Redwood City Series C $75.9M 2026-06-18 $289.6M Premji Invest, Synetro Group 51 to 100 2020

Table 2. Biotech startups that raised Series C in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 10 3% 2 Delix Therapeutics, Terrestrial Bio
2 Bristol-Myers Squibb Venture capital firm New York, United States 8 2% 2 BigHat Biosciences, Ratio Therapeutics
3 OrbiMed Private equity firm New York, United States 8 2% 3 Triveni Bio, Terremoto Biosciences, Aspen Neuroscience
4 National Science Foundation Entrepreneurship program Alexandria, United States 7 2% 1 Culture Biosciences
5 Khosla Ventures Venture capital firm Menlo Park, United States 6 2% 2 Prellis Biologics, Loyal
6 Y Combinator Startup accelerator Mountain View, United States 5 1% 1 Culture Biosciences
7 Temasek Private equity firm Singapore 5 1%
8 Alumni Ventures Angel group Manchester, United States 5 1%
9 Gaingels Syndicate Burlington, United States 4 1% 2 Delix Therapeutics, BigHat Biosciences
10 Cormorant Asset Management Hedge fund Boston, United States 4 1% 1 Triveni Bio
11 Alexandria Venture Investments Venture capital firm Pasadena, United States 4 1% 2 Triveni Bio, Aspen Neuroscience
12 Invus Private equity firm New York, United States 4 1% 1 Triveni Bio
13 Insight Partners Private equity firm New York, United States 4 1%
14 Wellington Management Private equity firm Boston, United States 4 1%
15 T. Rowe Price Private equity firm Baltimore, United States 4 1%

Table 3. Biotech startups that raised Series C in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 312 92% $35.6B
Software 38 11% $6.7B
Artificial intelligence 18 5% $4.3B
Hardware 15 4% $1.8B
Energy 4 1% $245.8M
Fintech 4 1% $543.0M

Table 4. Biotech startups that raised Series C in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series C 339 100% $32.5M

Table 5. Biotech startups that raised Series C in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
San Francisco 26 8%
San Diego 26 8%
Cambridge 23 7%
Boston 14 4%
Menlo Park 12 4%
Austin 9 3%
New York 9 3%
Seattle 8 2%
South San Francisco 8 2%
Waltham 6 2%
San Carlos 6 2%
San Mateo 5 1%

Table 6. Biotech startups that raised Series C in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 2 7% $115.0M
October 2026 1 3% $62.0M
September 2026 3 10% $208.1M
August 2026 1 3% $110.0M
July 2026 5 17% $551.0M
June 2026 4 14% $310.9M
May 2026 2 7% $20.0M
April 2026 1 3% $108.0M
March 2026 3 10% $177.0M
February 2026 2 7% $160.0M
January 2026 3 10% $320.0M
December 2025 1 3% $80.0M
November 2025 1 3% $115.0M

Table 7. Biotech startups that raised Series C in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 27 8% $2.1B
2025 27 8% $1.9B
2024 26 8% $2.2B
2023 15 4% $808.6M
2022 28 8% $2.0B
2021 31 9% $2.5B

Table 8. Biotech startups that raised Series C in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 3 1%
2020 to 2022 12 4%
2015 to 2019 95 28%
2010 to 2014 79 23%
Before 2010 149 44%

Table 9. Biotech startups that raised Series C in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 42 12%
11 to 50 151 45%
51 to 100 68 20%
101 to 250 50 15%
251 to 500 13 4%
501 to 1,000 6 2%
1,001 to 5,000 2 1%
5,001 to 10,000 1 0%
10,001 or more 3 1%

Table 10. Biotech startups that raised Series C in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in the United States whose last round is Series C are on the list?
339, in the file dated 16 November 2026. 29 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 339 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series C in the United States: 339 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in United States

Other sectors that raised Series C in United States

Cite: FundingWatcher, 339 biotech companies in the United States whose most recent round is Series C, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-c/united-states/